Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Deszk – page 20

383 clinical trials in Deszk, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Deszk at a glance
383
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

383 trials in Deszk

Open in trial search

Study on OM-85 for Preventing Respiratory Infections in Children with Wheezing Illness (Ages 6 Months to 5 Years)

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years
  • Sponsor:OM Pharma SA

Study on Long-Term Safety of Secukinumab for Patients with Polymyalgia Rheumatica

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Crohn's disease

Not recruiting

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Secukinumab and Prednisone for Patients with Polymyalgia Rheumatica Who Have Recently Relapsed

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Cardiac failure+1

Not recruiting

Study of LY3540378 for Adults with Worsening Chronic Heart Failure with Preserved Ejection Fraction

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Volenrelaxin
  • Sponsor:Eli Lilly & Co.

Obesity

Not recruiting

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Obesity+1

Not recruiting

Study comparing two forms of cagrilintide with placebo for weight loss in adults with overweight or obesity

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Obesity

Not recruiting

Study of KAI-9531 in Adults With Obesity or Overweight and Weight-Related Health Problems Without Diabetes

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:HRS 9531
  • Sponsor:Kailera Therapeutics Inc.

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

A study comparing the effectiveness of vorolanib and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyepoint Inc.

Asthma

Not recruiting

Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Chiesi Farmaceutici S.p.A.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Deszk

What the registry says about research in the country

01 Lung Cancer Research

Innovative clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, particularly targeting advanced and unresectable cases.

  • Advanced Non-Squamous NSCLC with HER2 Mutations
  • Stage III Unresectable NSCLC
  • Combination Therapy Approaches

Studies evaluating novel therapeutic agents including zongertinib and combination treatments with durvalumab plus domvanalimab to improve patient outcomes.

02 Targeted Therapies

Research examining personalized treatment approaches for patients with specific genetic markers and protein expressions.

  • HER2 Mutation-Targeted Treatments
  • PD-L1 Expression Analysis
  • Immunotherapy Combinations

Investigations comparing new targeted therapies against standard-of-care treatments for better progression-free survival.

03 Treatment Innovation

Advancement in therapeutic strategies for locally advanced lung cancer patients.

  • Chemoradiation Therapy
  • Novel Drug Combinations
  • Biomarker-Driven Research

Focus on developing improved treatment options for patients with unresectable stage III NSCLC following concurrent chemoradiation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.